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Abstract
 
The Src family kinase Lyn initiates intracellular signal transduction by associating with a variety
of immune receptors such as antigen receptor on B cells and high-affinity Fc receptor (FcR) for
immunoglobulin Ig(E) (Fc
 
e
 
RI) on mast cells. Involvement of Lyn in the IgE-mediated imme-
diate-type hypersensitivity is well documented, but the physiological significance of Lyn in
IgG-dependent, type III low-affinity FcR for IgG (Fc
 
g
 
RIII)-mediated responses is largely un-
known. In this study, we generated a double-mutant mouse strain deficient in both type II FcR
for IgG (Fc
 
g
 
RIIB) and Lyn to exclude any involvement of inhibitory signaling by Fc
 
g
 
RIIB,
which otherwise downregulates Fc
 
g
 
RIII-mediated cellular responses. Fc
 
g
 
RIIB-deficient but
Lyn-sufficient mice served as controls. The Lyn deficiency attenuated IgG-mediated systemic
anaphylaxis in vivo, and significantly reduced calcium mobilization and degranulation responses
of bone marrow–derived mast cells (BMMCs) in vitro. However, we found that either interleu-
kin 4 or tumor necrosis factor 
 
a
 
 release by BMMCs was comparable to that from Lyn-deficient
and control mice, and the reverse-passive Arthus reaction was equally induced in both mutant
mice, indicating that Lyn is not involved in the onset of the IgG-mediated, Fc
 
g
 
RIII-dependent
late phase responses of mast cells. These findings provide us with insight into distinct signaling
mechanisms in mast cells underlying the development of diverse pathologies as well as a thera-
peutic potential for selective treatment of allergic disorders.
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Introduction
 
Fc receptors (FcRs) expressed on immune effector cells are
capable of initiating a variety of immune and inflammatory
responses in an antibody-dependent manner. Because of
the complexity stemming from overlapped FcR expression
on diverse cell types, the defined role of each class of FcR
had not been assigned until recent efforts to generate sev-
eral strains of mice genetically deficient in FcR expression.
Currently, their roles are implicated not only in host de-
fense but also in the development of such diverse diseases
as allergy (1, 2), Arthus reaction (3, 4), rheumatoid arthritis
(5, 6), immune glomerulonephritis (7, 8), autoimmune
vasculitis (9), systemic lupus erythematosus (10), and
Goodpasture’s syndrome (11). The findings obtained from
these mutant mice have promoted an understanding of the
indispensable role of each FcR in a variety of immune pro-
cesses (for reviews, see references 12–14).
As notable findings in association with our current study,
previous studies have defined the central role of low-affinity
 
stimulatory FcR for IgG, Fc
 
g
 
RIII, on mast cells in initiating
two distinct classes of immune responses, that is, the IgG-
dependent anaphylaxis (15–17) and the reverse-passive
Arthus reaction (3, 4, 18–20). These in vivo experimental
models of inflammation are mutually distinguishable by the
time of disease onset and their histological features. Anaphy-
laxis displays edematous lesions in skin or systemic insuffi-
ciency of blood supply (shock) immediately after antigen
challenge, whereas the Arthus reaction appears as bleeding
and tissue-damaged lesions and takes several hours for their
development after antigen challenge. To date, pathogenesis
of these distinctive models has been interpreted as a conse-
quence of time-constrained releases of proinflammatory
mediators, for example, prestored factors such as histamine
and serotonin, or de novo synthesized factors such as arachi-
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donic acid metabolites and cytokines. However, an intracel-
lular mechanism underlying the pathogenesis of these mod-
els remains unclear.
Lyn is a Src family tyrosine kinase which functions to
initiate intracellular signal transduction by associating with
a variety of immune receptors bearing the cytoplasmic
amino acid motif termed immunoreceptor tyrosine–based
activation motif (ITAM),
 
1
 
 which serves as the binding se-
quence recognized by the Src homology 2 domain of cyto-
plasmic tyrosine kinase (21, 22). A recent study using Lyn-
deficient mice demonstrated the essential role of Lyn in
normal functions of B cells and mast cells in vivo (23–25).
In fact, Lyn-deficient mice displayed markedly impaired
anaphylactic response to IgE plus antigen challenge in skin,
suggesting a critical role of Lyn in Fc
 
e
 
RI-mediated signal
transduction (26).
In this study, we examined whether Lyn-deficient mice
could display the intact function of Fc
 
g
 
RIII, which associ-
ates with FcR
 
b
 
 and FcR
 
g
 
, the same ITAM-bearing sub-
units as Fc
 
e
 
RI, and which serves as the main initiator of
IgG-mediated immune responses in mice (for a review, see
reference 12). To achieve this objective, we first prepared
double-homozygous mice bearing null mutations for Lyn
(24) and Fc
 
g
 
RIIB (27). Since Fc
 
g
 
RIIB affects Fc
 
g
 
RIII-
mediated signaling by its inhibitory nature when these two
FcRs are present on a cell, as in the case of mast cells (17,
27), the removal of Fc
 
g
 
RIIB makes it possible to assess the
net effect of Fc
 
g
 
RIII-mediated stimulation on the onset of
diseases. Using these double-mutant mice, we obtained re-
sults that demonstrated the dispensable role of Lyn in cyto-
kine production in mast cells and in the onset of reverse-pas-
sive Arthus reaction in contrast to its indispensable role in
IgG-mediated anaphylactic response. Current findings pro-
vide an insight into distinct signaling mechanisms in mast
cells underlying the development of diverse pathologies and
suggest a way for selective treatment of hypersensitivities.
 
Materials and Methods
 
Mice. 
 
All experiments were performed using 7–12-wk-old
mice housed under conditions monthly certified as being specific-
pathogen free. The mice homozygous of null mutations in both
Lyn and Fc
 
g
 
RIIB (Lyn
 
2
 
IIB
 
2
 
) were generated by serial cross-
breeding between Lyn
 
2
 
/
 
2 
 
(24) and Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 (27) strains of
mice. Their littermates of Lyn
 
1
 
/
 
2
 
Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 (IIB
 
2
 
) were used
as control mice.
 
Cells and Antibodies. 
 
Bone marrow–derived mast cells (BM-
MCs) were obtained from a culture of bone marrow cells in
RPMI 1640 supplemented with 5 ng/ml murine IL-3 (R&D
Systems), 10% FCS, nonessential amino acids (GIBCO BRL),
100 IU/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 10 
 
m
 
M 2-ME.
To obtain the different type of cultured mast cells, BMMCs were
further cultured on confluent monolayer of Swiss 3T3 fibroblasts
(American Type Culture Collection) in the same medium for
 
2 wk. We used the BMMCs tightly adhered to monolayer cells
(3T3-BMMCs) for our assays. Peritoneal resident mast cells
(PMCs) were collected by peritoneal washings with Tyrode’s so-
lution supplemented with heparin (5 U/ml). Positive cells for
mouse c-kit staining were analyzed as PMCs. Mouse anti-trini-
trophenyl hapten (TNP) IgE (IGELa2; American Type Culture
Collection) and mouse anti-TNP IgG1 (G1; reference 28) were
prepared with DEAE-cellulose column chromatography from
hybridoma culture supernatants. Rat anti–mouse Fc
 
g
 
RII/III
(2.4G2; BD PharMingen), anti–mouse c-kit (2B8; BD PharMin-
gen), rabbit IgG anti-OVA (Sigma-Aldrich), F(ab
 
9
 
)
 
2
 
 fragment of
goat anti–rat IgG (Immunotech), and mouse antiphosphotyrosine
antibody (4G10; Upstate Biotechnology) were purchased.
 
Induction of Passive Systemic Anaphylaxis. 
 
Each mouse was
sensitized by intravenous administration of 200 
 
m
 
g anti-TNP IgG
or 20 
 
m
 
g anti-TNP IgE. At 30 min (IgG sensitization) or 24 h
(IgE sensitization) after the sensitization, anaphylaxis was induced
by intravenous administration of 1 mg TNP-conjugated OVA
(Sigma-Aldrich) in 100 
 
m
 
l PBS per mouse. Control mice re-
ceived PBS in place of antibody for sensitization. Rectal temper-
ature was monitored at various time points after induction using a
rectal probe coupled to a digital thermometer (Natsume Sei-
sakusyo Co.).
 
Measurements of Degranulation and Cytokine Release. 
 
BMMCs
(5
 
 3
 
 10
 
5
 
/ml) were labeled with 6.6 
 
m
 
Ci/ml of 5-[1,2-
 
3
 
H]-
hydroxytryptamine creatinine sulfate (American Radiolabeled
Chemicals, Inc.) for 16 h, and sensitized with 5 
 
m
 
g/ml 2.4G2 or
1 
 
m
 
g/ml of mouse anti-TNP IgE for 30 min of the labeling pe-
riod. After unbound antibodies were washed out, the receptor of
interest was aggregated with 0.3–10 
 
m
 
g/ml F(ab
 
9
 
)
 
2
 
 fragment of
goat anti–rat IgG or 0.03–30 ng/ml TNP-OVA for 1 h. The per-
centage of serotonin release (percent degranulation) was calcu-
lated as described previously. For cytokine measurements, BM-
MCs (5 
 
3
 
 10
 
4
 
 per sample) and 3T3-BMMCs (10
 
5
 
 per sample)
without the labeling process were stimulated as described above,
and culture supernatant was harvested at 3–12 h after induction
for TNF-
 
a
 
 or IL-4 measurement, respectively. The amount of
released cytokine was measured by ELISA kit (BD PharMingen).
Tissue extract samples were prepared from punched-out skin
specimens (12.5 mm
 
2
 
) at 3 h after induction of reverse-passive
Arthus reaction. Tissue specimens were homogenized in 400 
 
m
 
l
PBS containing 2 mM EDTA, 1 mM PMSF, 10 
 
m
 
g/ml aproti-
nin, 5 
 
m
 
g/ml leupeptin, and 2 
 
m
 
g/ml pepstatin. The amount of
TNF-
 
a
 
 in supernatant was measured with ELISA.
 
Analysis of Cytoplasmic Calcium Mobilization. 
 
BMMCs la-
beled with 2 
 
m
 
M Fura-2/acetoxymethyl ester (Molecular Probes)
were sensitized with 2 
 
m
 
g/ml biotinylated mouse anti-TNP IgE
or 5 
 
m
 
g/ml biotinylated 2.4G2 for 10 min at 25
 
8
 
C. Free antibody
was washed out, after which the cells were stimulated with 10 
 
m
 
g
of streptavidin (Wako Pure Chemicals) in 2 ml PBS containing 1
mM CaCl
 
2
 
 and 1 mM MgCl
 
2
 
. Cytoplasmic calcium mobilization
was monitored at a 510-nm emission wavelength excited by 340
and 360 nm with a fluorescence spectrophotometer (model
F4500; Hitachi Ltd.). Calibration and calculation of calcium con-
centration were performed as described (29).
 
Immunoblot Analyses. 
 
BMMCs (10
 
6
 
) sensitized with 2.4G2
or biotinylated mouse IgE were treated with 30 
 
m
 
g/ml F(ab
 
9
 
)
 
2
 
fragment of goat anti–rat IgG or 5 
 
m
 
g/ml streptavidin for 0.5, 1,
and 5 min at 37
 
8
 
C in 100 
 
m
 
l PBS supplemented with 1 mM
CaCl
 
2
 
 and 1 mM MgCl
 
2
 
. The treatment was terminated by add-
ing an equal volume of ice-chilled lysis buffer (50 mM Tris-HCl,
pH 7.4, 1% NP-40, 137 mM NaCl, 2 mM EDTA, 50 mM NaF,
2 mM NaVO
 
4
 
, 1 mM PMSF, 10 
 
m
 
g/ml aprotinin, 5 
 
m
 
g/ml leu-
 
1
 
Abbreviations used in this paper:
 
 BMMC, bone marrow–derived mast cell;
ITAM, immunoreceptor tyrosine–based activation motif; MPO, myelo-
peroxidase; PMC, peritoneal resident mast cell; TNP, trinitrophenyl. 
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peptin, 2 
 
m
 
g/ml pepstatin). The cell extract cleared of nuclear
fraction was used for the detection of protein phosphorylation.
Immunoblotting was performed with antiphosphotyrosine mono-
clonal antibody (4G10).
 
Flow Cytometric Analysis. 
 
Expression level of Fc
 
e
 
RI and Fc-
 
g
 
RIII on mast cells was measured by staining with mouse IgE
plus FITC-conjugated anti–mouse IgE and R-phycoerythrin (R-
PE)–conjugated anti–mouse Fc
 
g
 
RII/III (2.4G2), respectively.
Background levels of Fc
 
e
 
RI and Fc
 
g
 
RIII stainings for the cul-
tured mast cells were shown by single staining of FITC–anti-IgE
and R-PE–conjugated rat IgG2b isotype control antibody, re-
spectively. In the case of PMCs, we used the PMC from Fc-
 
g
 
RIIB-FcR
 
g
 
 double deficient mice, in which cell surface expres-
sion of Fc
 
e
 
RI and Fc
 
g
 
RIII is diminished, as a negative control to
determine the level of background signal. Increased expression of
Fc
 
e
 
RI on BMMCs was observed after the culture for 24 h in the
presence of 1 
 
m
 
g/ml of IgE. Flow cytometric analyses were per-
formed with a FACSCalibur™
 
 
 
(Becton Dickinson), and c-kit–
positive cells in 3T3-BMMCs and PMCs were analyzed as mast
cells.
 
Histologic and Cytologic Examinations.
 
Paraffin-embedded skin
sections were prepared after fixation in 10% (vol/vol) neutral-
buffered formalin. Peritoneal cells were placed onto slide glass
plate by cytospin centrifugation and fixed as above. Specimens
were stained with toluidine blue dye, pH 2.5, or hematoxylin
and eosin.
 
Reverse Cutaneous Arthus Reaction. 
 
Mice intradermally re-
ceived 20 
 
m
 
l of saline containing 0, 16, and 80 
 
m
 
g of rabbit anti-
OVA in a discrete spot on the shaved back of the trunk, and im-
mediately thereafter received 200 
 
m
 
l of saline containing 1 mg of
OVA intravenously. Mice were killed at 8 h, and the dorsal skins
were harvested. Myeloperoxidase (MPO) assay was performed as
described by Bradley et al. (30). In brief, the punched-out area
(12.5 mm
 
2
 
) of lesion of interest was homogenized in 400 
 
m
 
l of 50
mM phosphate buffer, pH 6.0, and further extracted by adding
hexadecyltrimethylammonium bromide (HTAB; Sigma-Aldrich)
to 0.5%, followed by sonication for 20 s and three cycles of freez-
ing and thawing. The supernatant of extract obtained by centrifu-
gation at 14,000 rpm for 15 min was used for measurement of
MPO activity. 20 
 
ml of the supernatant was mixed with 200 ml of
50 mM phosphate buffer, pH 6.0, containing 0.167 mg/ml o-dia-
nisidine dihydrochloride (Sigma-Aldrich) and 0.0005% hydrogen
peroxide (Wako Pure Chemicals), and color change was mea-
sured with light absorbance at 460 nm. 1 U of MPO activity was
arbitrarily defined as the activity given by 0.25 ml of mouse whole
blood. 
Results
Impaired FcgRIII Function for Passive Systemic Anaphylaxis
Induction in Lyn-deficient Mice.  Previous studies have
shown that Lyn-deficient mice failed to display IgE-depen-
dent passive cutaneous anaphylaxis, suggesting a critical
role of Lyn in triggering the signal downstream of FceRI
on mast cells (23). We further examined the role of Lyn in
triggering the signal downstream of FcgRIII by inducing
passive systemic anaphylaxis with IgG immune complexes.
In all experiments in this report, we used a double-mutant
mouse strain of Lyn and FcgRIIB (Lyn2IIB2) to eliminate
involvement of FcgRIIB, which exerts an inhibitory func-
tion on FcgRIII-mediated responses (13, 17, 27). We in-
duced systemic anaphylaxis in Lyn-deficient and control
mice by challenging with hapten-specific antibody (anti-
TNP IgG or anti-TNP IgE) and antigen (TNP-OVA)
through the tail vein. Decrease in rectal temperature was
monitored as a measure of systemic anaphylactic response.
Both in IgG- and IgE-based stimulations, Lyn-deficient
mice displayed markedly reduced responses, whereas the
control mice showed substantial responses (Fig. 1). The
finding of impaired responsiveness in Lyn-deficient mice
indicates that activation of Lyn in mast cells is necessary for
intact anaphylactic response triggered by FcgRIII as well as
by FceRI.
Reduced FcgRIII Functions Detectable in BMMCs from Lyn-
deficient Mice.  Using BMMCs in culture, we examined
mast cell function by measuring serotonin release, which is
a consequence of mast cell degranulation, a representative
of immediate-phase responses, and a critical event that leads
to anaphylaxis. We induced mast cell activation with
graded cross-linking of FcgRIII or FceRI, and measured
radiolabeled serotonin released into the culture medium
(Fig. 2). Upon either FcgRIII- or FceRI-mediated stimu-
lation, degranulation responses of Lyn-deficient BMMCs
were significantly low within the range of low grade stimu-
lation, that is, 1–3 mg/ml for anti–rat IgG or 0.3–3 ng/ml
for TNP-OVA, although comparable degranulation was
achieved within the range of high grade stimulation in
Lyn-deficient BMMCs. These differences between Lyn-
deficient and control mice were further confirmed in three
experiments using two independently established mast cell
cultures. We next examined intracellular defective traits in
Lyn-deficient BMMCs by detecting cytoplasmic calcium
mobilization and tyrosine phosphorylation of whole cellu-
lar proteins (Fig. 3, A and B). We used biotin-conjugated
antibodies and streptavidin for BMMC stimulation. This
Figure 1. Passive systemic anaphylaxis (SA) in Lyn2IIB2 and control
mice (IIB2). Anaphylaxis was induced with intravenous administration of
200 mg of anti-TNP IgG1 (left, n 5 4) or 20 mg of anti-TNP IgE (right,
n 5 6) followed by 1 mg of TNP-OVA antigen per mouse. Control ex-
periments were performed as well except for antibody injection (upper
figures). Anaphylaxis was periodically monitored by changes in rectal
temperature from the time of antigen injection. Mean 6 SD. *P , 0.01
(Student’s t test).566 Onset of Arthus Reaction is Lyn Independent
mode of stimulation had been determined to be equivalent
to the high grade stimulation for degranulation assay. To
either FcgRIII- or FceRI-mediated stimulation, the Lyn-
deficient BMMCs displayed a reduced calcium mobiliza-
tion. This response was especially affected in the early
phase (,150 s) of induction, but substantially induced in
the late phase (.300 s; Fig. 3 A). As long as it was observed
at 5 min after stimulation, induction of tyrosine phosphor-
ylation was markedly affected in Lyn-deficient BMMCs
(Fig. 3 B).
Normal FcR Expression and Development of Mast Cells in
Lyn-deficient Mice.  Lyn has been shown to be involved
not only in the FcR-mediated but also in c-kit–mediated
signal transduction (31–33). As the c-kit–mediated growth
signal is especially important for the development of mast
cells in vivo, the question arises whether Lyn deficiency
could affect the development of mast cells in vivo. If so,
this consequence could account for the defect of mast cell–
related phenotypes in Lyn-deficient mice. To address this
issue, we examined mast cell phenotypes of Lyn-deficient
and control mice for various mast cell preparations. In this
study, we prepared c-kit–dependent mast cells by cocultur-
ing BMMCs for 2 wk with Swiss 3T3 fibroblastic cell line
(3T3-BMMCs), which serve as c-kit ligand and make BM-
MCs differentiate towards the connective tissue-type mast
cells (34). The detection of mast cells in vivo was done by
histological preparation with toluidine blue staining. The
results clearly revealed that Lyn deficiency in 3T3-BMMCs
and PMCs as well as in BMMCs does not affect the steady
expression of c-kit (data not shown), FceRI, and FcgRIII
(Fig. 4 A). We also observed normal increase of FceRI ex-
pression on Lyn-deficient BMMC by monomeric IgE
binding (Fig. 4 A). Importantly, resident mast cells in skin
and PMCs from Lyn-deficient and control mice were mu-
tually indistinguishable in cell number, cell shape, cell size,
and intracellular granule density (Fig. 4 B). These findings
indicate the normal development of mast cells in Lyn-defi-
cient mice. Accordingly, we concluded that defective phe-
notypes in Lyn-deficient mast cells and mice are not be-
cause of lowered expression of FcRs and developmental
abnormality, and thus Lyn is central to the activation of
FcR-mediated signal transduction for the immediate phase
of mast cell activation.
Normal FcgRIII Function for Cytokine Production in BMMCs
from Lyn-deficient Mice.  It has been shown that FcR-
mediated stimulation causes de novo synthesis of cytokines
in mast cells (35–39). TNF-a and IL-4, well-analyzed cy-
tokines in association with mast cell activation, are known
to be released at a few and several hours, respectively, after
FcR-mediated stimulation. The cytokine releases of mast
cells have been shown to be important for development of
mast cell–related tissue injuries (9, 40, 41) and allergic phe-
notypes (42). In this respect, we further examined the effect
of Lyn depletion on TNF-a and IL-4 production as a
Figure 2. Degranulation responses of Lyn2IIB2 and control (IIB2)
BMMCs. Degranulation of BMMCs was evoked by FcgRIII or FceRI
aggregation with rat anti-FcgRII/III (2.4G2) plus F(ab9)2 goat anti–rat
IgG (left), or anti-TNP IgE plus TNP-OVA (right), respectively. De-
granulation was evaluated 1 h after stimulation with the release of seroto-
nin into culture medium as described in Materials and Methods. Data
represent the mean percentage of duplicate samples.
Figure 3. Cytoplasmic Ca21 mobilization (A) and tyrosine phosphory-
lation of whole cellular protein (B) in Lyn-deficient and control BMMCs
induced by FcR cross-linking. (A) Fura-2–loaded BMMCs of Lyn2IIB2
(left) and control (IIB2, right) mice were treated with biotinylated anti-
FcgRII/III (*2.4G2) or **biotinylated IgE followed by streptavidin cross-
linking (arrow). Calcium mobilization was detected as 510-nm emission
with a fluorospectrophotometer. (B) BMMCs were treated as in A, and
FcR-mediated stimulation was terminated by adding lysis buffer at the in-
dicated time points. Cell lysates (2.5 3 104 equivalents per lane) pre-
cluded of nuclear fractions were used for immunoblotting with antiphos-
photyrosine monoclonal antibody (anti-pTyr, 4G10). Relative molecular
masses are indicated.567 Yuasa et al.
downstream event of FcR-mediated stimulation. The 3T3-
BMMCs and BMMCs were stimulated for several hours
in the presence of anti-FcgRII/III (2.4G2) and graded
amounts of secondary antibody for FcgRIII cross-linking.
We measured the amount of IL-4 and TNF-a in culture
medium with ELISA at 12 and 3 h, respectively, after cross-
linking. The results clearly demonstrated no defects in
TNF-a and IL-4 induction in Lyn-deficient 3T3-BMMCs
(Fig. 5) as well as in BMMCs (data not shown), indicating
that the signaling pathway downstream of FcgRIII is linked
to cytokine production independently of Lyn activation in
mast cells. The paralleled experiments using 3T3-BMMCs
and BMMCs with FceRI cross-linking also gave rise to the
results indicating no defect in cytokine induction (data not
shown). These findings sharply contrast with the attenuated
induction of immediate phase responses in Lyn-deficient
mice and BMMCs as shown in Figs. 2 and 3, suggesting the
distinctive signaling pathways associated with immediate
and late phase responses of mast cells.
Normal FcgRIII Function for Reverse Cutaneous Arthus Re-
action in Lyn-deficient Mice. The in vitro results for Lyn-
independent cytokine induction prompted us to examine
the role of Lyn in reverse-passive Arthus reaction. It has
been shown that this model represents an immune com-
plex–triggered mode of inflammation in vivo, and that its
onset in the murine model largely depends on FcgRIII-
mediated mast cell activation (3, 4, 15, 16, 19). TNF-a is
known to play a pivotal role in recruitment of neutrophils
in mast cell–dependent cutaneous injury (43, 44). We ex-
amined the onset of reverse-passive Arthus reaction in Lyn-
deficient mice after the treatment with intradermal injec-
tions of anti-OVA rabbit IgG followed by OVA challenge
through the tail vein. Diseased reaction was evaluated by
these three means: (a) histopathological feature; (b) MPO
activity in situ at the late inflamed phase (8 h), which paral-
Figure 4. Normal features of Lyn-deficient mast cells. (A) Histograms for cell
surface expression of FceRI and FcgRIII on IL-3–dependent BMMCs, BMMCs
cocultured with Swiss 3T3-BMMCs, and PMCs. FceRI and FcgRIII expression
was detected by mouse IgE plus FITC-conjugated anti–mouse IgE and PE-conju-
gated anti–mouse FcgRII/III (2.4G2), respectively (solid line). Background stain-
ing was traced with a single second antibody or isotype-matched antibody staining
in the case of BMMCs and 3T3-BMMCs, or with full-stained mast cells prepared
from FcgRIIB and FcRg double deficient mice, which lack expression of all
FcRs on mast cells, in the case of PMCs. Increased expression of FceRI after IgE
incubation (1 mg/ml, 24 h) was shown with BMMCs (bold line with IgE1). FcgRIII expression was unchanged after this treatment (bold line). (B) Pho-
tomicrographs of mast cells resident in skin and peritoneal cavity. Mast cells are shown by metachromatic staining with toluidine blue dye (pH 2.5), and
in skin sections are indicated by arrowheads. PMC preparation was made with cytospin centrifugation. Original magnifications: 3100 for skin sections;
31,000 for PMC preparations. PEC, peritoneal cells.
Figure 5. Cytokine release from Lyn2IIB2 and control (IIB2) 3T3-
BMMCs (105) evoked by FcgRIII aggregation. BMMCs were stimulated
the same way as in the degranulation assay except for the time point for
sample harvest. Culture supernatants at 12 or 3 h after stimulation were
used for measurement of IL-4 (left) or TNF-a (right) release, respec-
tively. Each column represents the mean 6 SD of IL-4 (ng/105 cells) and
TNF-a (pg/105 cells) obtained from triplicate assays.568 Onset of Arthus Reaction is Lyn Independent
leled the extent of PMN infiltration; and (c) TNF-a release
at the initial phase (3 h). We first showed that Lyn-defi-
cient mice as well as control mice display inflammatory tis-
sue damage with massive neutrophil infiltration in the chal-
lenged sites (Fig. 6 A). Consistently, comparable induction
of MPO activity in situ was detected in these two strains of
mice (Fig. 6 B). We next examined increase of TNF-a
production at the initial phase of the Arthus reaction in the
challenged sites (dorsal skin and ear). Although the results
from two different lesions are somewhat unparallel, there
was found to be no statistic significance in the TNF-a pro-
duction between Lyn-deficient and control mice (Fig. 6
C). This finding cannot affirm the intact TNF-a produc-
tion in Lyn-deficient mice; however, it may mean that in
vivo mechanisms for TNF-a production are not affected as
much as mechanisms for the immediate phase reaction in
Lyn-deficient mice. Collectively, these findings indicate
that activation of the Lyn-independent signaling pathway
downstream of FcgRIII is sufficient for initiating the re-
verse-passive Arthus reaction, suggesting that Lyn is not
necessary for the onset of late phase responses of mast cells.
Discussion
The FcgRIIB deficiency made it possible to examine
FcgRIII function in mast cell activation, whereas Lyn defi-
ciency provided us with an opportunity to reevaluate the
nature of signaling mechanisms leading to various types of
immune responses in vivo. By introducing both deficien-
cies in mice, we investigated the nature of FcgRIII func-
tion in relation to mast cell–dependent pathogenesis. The
notable points of the present findings are summarized as
follows. (a) Lyn is required for intact induction of immedi-
ate phase responses as revealed in the degranulation re-
sponse and systemic anaphylaxis (Figs. 1–3). Since Lyn is
unlikely to be involved in mechanisms for FcR expression
and maturation of mast cell in vivo (Fig. 4), the defect in
immediate phase responses in Lyn-deficient mice can be
interpreted as a consequence of the defect in signal trans-
duction downstream of FcRs. (b) In contrast, Lyn is dis-
pensable for late phase responses as revealed in cytokine in-
duction and the reverse-passive Arthus reaction (Figs. 5 and
6). These contrasting results imply that Lyn-dependent and
-independent signaling pathways downstream of FcgRIII
underlie the onset of the anaphylactic response and the
Arthus reaction, respectively. Consistent with our present
results, two independent studies have demonstrated that
Lyn-deficient mice do not display passive cutaneous ana-
phylaxis triggered by IgE plus antigen (23), while Lyn-defi-
cient BMMCs were capable of activating such cytokine
genes as IL-4, IL-5, IL-6, and TNF-a in response to FceRI
aggregation (26). Thus, it is suggested that FcgRIII and
FceRI commonly involve Lyn-dependent and -indepen-
dent modes of signal transduction in triggering immediate
and late phase responses of mast cells in vivo, respectively.
It has been well documented that Lyn is physically and
functionally associated with cell surface receptors such as B
cell receptor (22, 45, 46), FceRI, FcgRIII on mast cells
(47), IL-2 receptor (48), and GM-CSF receptor (49, 50).
However, current findings have directed our interest to-
wards molecular mechanisms for a Lyn-independent signal-
ing pathway in mast cells. Previous studies have delineated
signaling events required for cytokine gene activation upon
FceRI aggregation. In those studies, inactivation of Btk
(51), cyclosporin A–sensitive calcium-dependent pathway
(52), phosphatidylinositol 3-kinase (53, 54), protein kinase
Cb (55), or c-Jun NH2-terminal kinase (JNK)-related
pathway (56, 57), respectively, caused attenuation of cy-
tokine gene activation. Accordingly, the Lyn-independent
pathway may involve activation of these diverse signaling
molecules in mast cells as well as the Lyn-dependent path-
way. Notably, the requirement of Btk for cytokine induc-
tion suggests the presence of a tyrosine kinase other than
Lyn upstream of Btk, because activation of Btk requires an-
other tyrosine kinase such as Lyn to phosphorylate Btk
Figure 6. Reverse-passive Arthus reaction in Lyn2IIB2 and control
(IIB2) mice evoked by IgG immune complexes. Each mouse was treated
with intradermal injection of 0 (PBS), 16, or 80 mg of rabbit anti-OVA
IgG per site followed by intravenous injection of 1 mg of OVA in 0.2 ml
saline. (A) Photomicrographs of a representative lesion of the Arthus reac-
tion at 8 h after antigen challenge. Hematoxylin and eosin staining. Orig-
inal magnifications: 340 or 31,000 as indicated in each photomicro-
graph. (B) MPO activity in a skin lesion at 8 h after antigen challenge.
Mean 6 SD of five mice is indicated. One unit represents MPO activity
in 0.25 ml of whole blood sample. (C) Amount of TNF-a released in skin
lesions at 3 h after antigen challenge. Each column represents the mean 6
SD of TNF-a density (pg/mm2) in skin lesions obtained from five mice.569 Yuasa et al.
(58–60). In fact, Nishizumi and Yamamoto have demon-
strated the activation of c-Src kinase on FceRI aggregation
in Lyn-deficient mast cells, and suggested a compensatory
mechanism for cytokine induction in place of Lyn (26).
However, it remains to be determined whether c-Src is
functionally sufficient for cytokine induction or not. Here,
we again support the presence of an undetermined tyrosine
kinase as a mechanism of Lyn-independent signal transduc-
tion that sufficiently functions for cytokine induction. The
mechanisms for time-constrained mast cell activation,
which leads to immediate and late phase responses, may be
attributed to the differential natures of Lyn and this puta-
tive tyrosine kinase.
There have been two conflicting results reported regard-
ing IgE-dependent anaphylaxis in Lyn-deficient mice.
Hibbs and Dunn have shown that Lyn-deficient mice dis-
played a defect in the induction of passive cutaneous ana-
phylaxis by IgE (21). On the other hand, Nishizumi and
Yamamoto have mentioned that Lyn-deficient mice were
capable of developing passive cutaneous anaphylaxis by
IgE, and that Lyn-deficient BMMCs indeed displayed no
defect in degranulation in response to FceRI aggregation
(26). In our current results, Lyn-deficient mice failed to ex-
hibit passive systemic anaphylaxis, whereas Lyn-deficient
BMMCs were found to be responsive to high dose stimula-
tion for FceRI. In conclusion, the Lyn-dependent pathway
serves as the immediate type of mast cell activation in vivo
in response to low dose, probably biologically feasible,
FcR-mediated stimulation.
Our findings indicate the presence of a Lyn-independent
signaling mechanism in mast cells, and its involvement in
cytokine induction and immune complex–triggered immu-
nity represented by the Arthus reaction. As a possible
mechanism for Lyn-independent signal transduction, a ty-
rosine kinase other than Lyn might be postulated for the
signaling events. This notion may provide a novel thera-
peutic approach to allergy, in which targeted blocking of
Lyn in mast cells can selectively suppress immediate-type
hypersensitivities without affecting a common, immune
complex–triggered immunity.
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